Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hegen

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
Therapeutic Advances in Neurological Disorders|October 8, 2020
Recent developments in MOG-IgG associated neurological disordersHarald Hegen, Markus Reindl
Neurology|July 30, 2025
Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple SclerosisGabriel Bsteh, Harald Hegen
Ebiomedicine|February 1, 2026
Letter in response to "Kappa free light chain index as a substitute to oligoclonal bands in diagnosing multiple sclerosis"Florian Deisenhammer, Harald Hegen
Neurology|September 5, 2012
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trialFlorian Deisenhammer, Harald Hegen
Handbook of Clinical Neurology|November 8, 2017
Vascular diseases and bleedingsHarald Hegen, Michael Auer, Florian Deisenhammer
Wiener Medizinische Wochenschrift (1946)|February 8, 2022
Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activityHarald Hegen, Klaus Berek, Florian Deisenhammer
Multiple Sclerosis and Related Disorders|February 10, 2020
Commentary to "Letter to the editor: To treat or not to treat study - Comparative group inclusion considerations" for multiple sclerosis and related disordersGabriel Bsteh, Harald Hegen, Thomas Berger
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2015
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-βHarald Hegen, Michael Auer, Florian Deisenhammer
Clinical Chemistry and Laboratory Medicine|April 16, 2014
Serum glucose adjusted cut-off values for normal cerebrospinal fluid/serum glucose ratio: implications for clinical practiceHarald Hegen, Michael Auer, Florian Deisenhammer
Expert Review of Molecular Diagnostics|March 27, 2024
Body fluid markers for multiple sclerosis and differential diagnosis from atypical demyelinating disordersAngelika Bauer, Harald Hegen, Markus Reindl
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
Therapeutic Advances in Neurological Disorders|October 8, 2020
Recent developments in MOG-IgG associated neurological disordersHarald Hegen, Markus Reindl
Neurology|July 30, 2025
Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple SclerosisGabriel Bsteh, Harald Hegen
Ebiomedicine|February 1, 2026
Letter in response to "Kappa free light chain index as a substitute to oligoclonal bands in diagnosing multiple sclerosis"Florian Deisenhammer, Harald Hegen
Neurology|September 5, 2012
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trialFlorian Deisenhammer, Harald Hegen
Handbook of Clinical Neurology|November 8, 2017
Vascular diseases and bleedingsHarald Hegen, Michael Auer, Florian Deisenhammer
Wiener Medizinische Wochenschrift (1946)|February 8, 2022
Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activityHarald Hegen, Klaus Berek, Florian Deisenhammer
Multiple Sclerosis and Related Disorders|February 10, 2020
Commentary to "Letter to the editor: To treat or not to treat study - Comparative group inclusion considerations" for multiple sclerosis and related disordersGabriel Bsteh, Harald Hegen, Thomas Berger
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2015
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-βHarald Hegen, Michael Auer, Florian Deisenhammer
Clinical Chemistry and Laboratory Medicine|April 16, 2014
Serum glucose adjusted cut-off values for normal cerebrospinal fluid/serum glucose ratio: implications for clinical practiceHarald Hegen, Michael Auer, Florian Deisenhammer
Expert Review of Molecular Diagnostics|March 27, 2024
Body fluid markers for multiple sclerosis and differential diagnosis from atypical demyelinating disordersAngelika Bauer, Harald Hegen, Markus Reindl
Pageof 17